FDA rejects Duchenne therapy, citing 'data integrity violations'
The FDA has turned down Capricor's cell therapy for Duchenne muscular dystrophy for a second time. It said the key study had "serious data integrity violations." Blinding rules were broken. The chief executive, Linda Marbán, says the company stands behind its data.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.